We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

300442:SZSERange Intelligent Computing Technology Group Company Limited Class A Analysis

Data as of 2026-07-29 - not real-time

CN¥60.72

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Range Intelligent Computing Technology Group posted a spectacular 53.6% revenue surge, delivering a gross margin of 45.6% and an operating margin near 39%, while its profit margin topped 80%. However, the balance sheet is heavily weighted with a debt‑to‑equity ratio above 160% and free cash flow turned sharply negative, raising concerns about cash generation. The DCF model values the shares at roughly 42.8 CNY, which is about 30% below the current market price of 60.7 CNY, suggesting the stock is overvalued on an intrinsic basis. Nevertheless, its trailing P/E of 19.5 sits well under the industry average of 31.5, giving a relative value edge.
Technical gauges show the stock sitting near its 20‑day SMA (≈72.7) but below the 50‑day SMA (≈78.8), with a neutral trend and an bearish MACD crossing, while the RSI of 31 points to oversold momentum. Volatility remains elevated at nearly 69% over the past month, and trading volume has been tapering, indicating waning liquidity. Investor sentiment is in the ‘Extreme Greed’ zone on the Fear‑Greed Index, which may be inflating price expectations. Given these mixed signals, the near‑term outlook leans toward caution.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price hovering just above the 58.6 support level
  • RSI at ~31 suggesting oversold conditions
  • Bearish MACD histogram indicating downward momentum

Medium Term

1–3 years
Neutral
Model confidence: 4/10

Key Factors

  • Revenue growth exceeding 50% YoY
  • Debt‑to‑equity ratio above 160% raising leverage concerns
  • Negative free cash flow undermining cash generation

Long Term

> 3 years
Cautious
Model confidence: 6/10

Key Factors

  • DCF fair value (~42.8) well below current price
  • High valuation multiples relative to intrinsic estimate
  • Sustained high debt and cash flow deficits limit long‑term upside

Key Metrics & Analysis

Financial Health

Revenue Growth53.60%
Profit Margin82.37%
P/E Ratio19.5
ROE35.67%
ROA3.74%
Debt/Equity167.49
P/B Ratio6.9
Op. Cash FlowCN¥3.7B
Free Cash FlowCN¥-8571821056
Industry P/E31.5

Technical Analysis

TrendNeutral
RSI31.8
SupportCN¥58.60
ResistanceCN¥92.00
MA 20CN¥72.67
MA 50CN¥78.79
MA 200CN¥72.62
MACDBearish
VolumeDecreasing
Fear & Greed Index86

Valuation

Fair ValueCN¥42.84
Target PriceCN¥109.43
Upside/Downside80.21%
GradeOvervalued
TypeGrowth
Dividend Yield1.02%

Risk Assessment

Beta0.74
Volatility68.96%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.